Alexander Sapir
Directeur Général chez FULCRUM THERAPEUTICS, INC.
Fortune : 309 870 $ au 30/04/2024
Postes actifs de Alexander Sapir
Sociétés | Poste | Début | Fin |
---|---|---|---|
PHASEBIO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 12/02/2020 | - |
Independent Dir/Board Member | 12/02/2020 | - | |
FULCRUM THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/07/2023 | - |
Directeur Général | 01/07/2023 | - | |
President | 01/07/2023 | - | |
Directeur Financier/CFO | 01/07/2023 | 07/08/2023 | |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Directeur/Membre du Conseil | 10/06/2019 | - |
Directeur Général | 10/06/2019 | - |
Historique de carrière de Alexander Sapir
Anciens postes connus de Alexander Sapir
Sociétés | Poste | Début | Fin |
---|---|---|---|
DOVA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/03/2017 | 01/04/2019 |
Directeur Général | 01/01/2017 | 01/12/2018 | |
President | 01/01/2017 | 01/12/2018 | |
UNITED THERAPEUTICS CORPORATION | Sales & Marketing | 01/01/2006 | 01/05/2016 |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Sales & Marketing | 01/01/2003 | 01/01/2005 |
Formation de Alexander Sapir
Harvard Business School | Masters Business Admin |
Franklin & Marshall College | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Royaume-Uni | 2 |
Opérationnelle
Director/Board Member | 4 |
Chief Executive Officer | 3 |
President | 2 |
Sectorielle
Health Technology | 7 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 3 |
---|---|
UNITED THERAPEUTICS CORPORATION | Health Technology |
PHASEBIO PHARMACEUTICALS, INC. | Health Technology |
FULCRUM THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 3 |
---|---|
Dova Pharmaceuticals, Inc.
Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
Guilford Pharmaceuticals, Inc.
Guilford Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Guilford Pharmaceuticals Inc. is a pharmaceutical company engaged in the research, development and commercialization of proprietary drugs that target the hospital and neurology markets. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer, for the treatment of brain cancer, and AGGRASTAT(R) Injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and peripheral nerve injury | Health Technology |
ReViral Ltd.
ReViral Ltd. BiotechnologyHealth Technology ReViral Ltd. specializes in the areas of virology and antiviral therapies. It offers drugs to treat respiratory synctial virus infection. The company was founded by Neil Matthews and Stuart Cockerill in 2011 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Bourse
- Insiders
- Alexander Sapir
- Expérience